Absence of clinically relevant drug-drug interaction between odanacatib and digoxin after concomitant administration

• Published in: International journal of clinical pharmacology and therapeutics Vol. 51; no. 8; p. 688
• Main Authors: Stoch, S Aubrey, Witter, Rose, Hreniuk, David, Liu, Chengcheng, Zajic, Stefan, Mehta, Anish, Brandquist, Christine, Dempsey, Cynthia, Degroot, Bruce, Stypinski, Daria, Denker, Andrew, Wagner, John A
• Format: Journal Article
• Language: English
• Published: Germany 01.08.2013
• Subjects: Adult; Biphenyl Compounds - administration & dosage; Biphenyl Compounds - adverse effects; Biphenyl Compounds - pharmacology; Digoxin - administration & dosage; Digoxin - adverse effects; Digoxin - pharmacokinetics; Drug Interactions; Female; Humans; Male; Middle Aged
• ISSN: 0946-1965
• DOI: 10.5414/CP201864

This study was conducted in order to assess the effect of multiple doses of odanacatib, a cathepsin (Cat)-K inhibitor, on the pharmacokinetics of digoxin. Twelve healthy male and female subjects received 0.5 mg digoxin and 50 mg odanacatib. This open label study was conducted to determine the effect of odanacatib on the plasma pharmacokinetics of immunoreactive digoxin. Subjects received a single oral dose of 0.5 mg digoxin followed by a 10-day washout, followed by 3 once-weekly oral doses of 50 mg odanacatib and co-administration with 0.5 mg digoxin with the last odanacatib dose. A linear mixed-effect model was used to analyze AUC0-120h. Safety and tolerability were assessed. The estimated geometric-mean-ratio (90% confidence interval) for AUC0-120h was 0.95 (0.89, 1.01), which was within (0.80, 1.25) determined to demonstrate a lack of interaction. There were no serious AEs, discontinuations due to AEs, or clinically significant abnormalities in ECG or vital sign measurements. This study demonstrated that 50 mg odanacatib did not lead to clinically important effects on the pharmacokinetics of 0.5 mg digoxin.